The unsolved mystery over missing $25 billion Hermes windfall
Eric Freymond worked for 24 years as a wealth manager to Hermes descendant Nicolas Puech before their relationship soured, leading to a court case in Geneva. The wealthy octogenarian Puech alleged that Freymond had played a role in the disappearance of some 6 million shares in Hermès International SCA that he had inherited.
A decision by an appeals court in Geneva last year found no evidence that Freymond mismanaged Puech's fortune or that the reclusive, fifth-generation heir was duped over an extensive period during which time at least some of the stock was sold. Freymond denied all allegations of wrongdoing.
Freymond's lawyer Yannis Sakkas confirmed the death, saying he was 'deeply shocked by the terrible news'. Freymond was 67.
The dispute over Puech's stake in Hermes was one of the most enduring mysteries in the fallout from one of France's most high-profile corporate battles. A recent twist came from a lawsuit filed in March in Washington, DC, in which Puech was accused of failing to deliver the $US16 billion of Hermes shares as part of a sale agreement. His lawyer said his client was not involved in the deal.
More than a decade ago, Bernard Arnault, luxury goods rival and founder of conglomerate LVMH, revealed he had stealthily amassed a stake in Hermes. Descendants controlling Hermès came together and successfully fought the unwelcome advance.
The fate of Puech's shares was never clarified, even after Arnault's 2014 agreement with the Hermes clan to start unwinding his stake. The enigma deepened in 2023, when Puech accused Freymond of mishandling his holdings.
The Hermes clan, which counts more than 100 members, is one of Europe's richest families. Should Switzerland-based Puech still hold his stake, he would be the single largest investor in the purveyor of Birkin handbags and colourful silk scarves that was founded in 1837.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
AU Financial Review
9 hours ago
- AU Financial Review
Retro remote work rules no fix for Victoria's productivity plunge
Victorian Labor Premier Jacinta Allan's pledge to enshrine in law public servants' and private sector workers' right to work from home at least two days a week may be smart short-term politics. However, it's typically poor public policy from Australia's most far-left government, whose long-term rule has coincided with Victoria's economic and financial decline. This includes cellar-dwelling labour productivity, which has grown more slowly in Victoria over the past decade than in any other state or territory. Allan's proposed legislation is likely to be struck down by a constitutional challenge in the High Court, legal experts warn. Yet the retail political purpose is to wedge the Liberal opposition ahead of the next state election due in November next year. Victorian Labor is aligning itself with the female voters who led the backlash that, during the federal election campaign, forced the Coalition to ditch its plan to force Canberra-based bureaucrats to work from the office full-time.
AU Financial Review
10 hours ago
- AU Financial Review
Why utilities are a top pick in Donald Trump's uncertain world
Utilities are among the top picks for international investment group Cohen & Steers as it reshuffles its holdings to minimise the impact of global tariffs and bets on rising demand for power from data centres to cope with the artificial intelligence boom. 'Utilities tend to have very little impact from tariffs,' said Ben Morton, the New York-based head of global infrastructure for the $US88 billion ($136 billion) asset manager during a trip to Sydney to meet with local investors.
AU Financial Review
12 hours ago
- AU Financial Review
Roundtable must reform the super performance test
Last week, French pharmaceutical company Sanofi announced a deal worth over $1 billion to buy a biotech firm with exclusive rights to a unique vaccine technology developed by Australian scientists. This is great news. The global player will buy into Vicebio, a London-based group, which is developing vaccines for two respiratory viruses using the molecular clamp technology invented by University of Queensland professors Paul Young, Daniel Watterson and Keith Chappell.
